**Core Concept**
Vismodegib is a targeted therapy designed to treat a specific type of skin cancer, basal cell carcinoma. It targets a key molecular pathway involved in the growth and development of these cancer cells.

**Why the Correct Answer is Right**
Vismodegib specifically inhibits the Hedgehog pathway, a signaling cascade that plays a crucial role in embryonic development and tissue patterning. The Hedgehog pathway is activated by the binding of Hedgehog ligands to their receptors, Patched (PTCH) and Smoothened (SMO). Vismodegib acts by inhibiting the activity of SMO, thereby preventing the activation of the Hedgehog pathway and inhibiting the growth and proliferation of basal cell carcinoma cells.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because Vismodegib does not target the PI3K/AKT pathway, which is involved in cell survival and proliferation but not the primary mechanism of action of Vismodegib.
**Option B:** This option is incorrect because Vismodegib does not inhibit the epidermal growth factor receptor (EGFR), which is a different molecular target involved in the growth and proliferation of various types of cancer cells.
**Option C:** This option is incorrect because Vismodegib does not target the mTOR pathway, which is involved in cell growth and metabolism but not the primary mechanism of action of Vismodegib.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that Vismodegib is a targeted therapy that specifically inhibits the Hedgehog pathway, making it a valuable treatment option for patients with basal cell carcinoma who have failed or are intolerant to other therapies.

**Correct Answer:** C. Smoothened (SMO)